Compass Pathways (FRA:5Y6) Short-Term Debt : €0.00 Mil (As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Compass Pathways Short-Term Debt?

Compass Pathways's Short-Term Debt for the quarter that ended in Mar. 2024 was €0.00 Mil.

Compass Pathways Short-Term Debt Historical Data

The historical data trend for Compass Pathways's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Compass Pathways Short-Term Debt Chart

Compass Pathways Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Short-Term Debt

Get a 7-Day Free Trial

18.98

Compass Pathways Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Short-Term Debt	Get a 7-Day Free Trial															-	-	-	-	-

Compass Pathways Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Compass Pathways Short-Term Debt Related Terms

Thank you for viewing the detailed overview of Compass Pathways's Short-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Compass Pathways (FRA:5Y6) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Compass Pathways PLC (FRA:5Y6) » Definitions » Short-Term Debt

Comparable Companies

Traded in Other Exchanges

CMPS:USA

Address

33 Broadwick Street, London, GBR, W1F 0DQ

Website

https://www.compasspathways.com

Compass Pathways PLC is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. The company is motivated by the need to find better ways to help and empower people suffering with mental health challenges who are not helped by existing therapies and are pioneering the development of a new model of psilocybin therapy, in which psilocybin is administered in conjunction with psychological support. Its focus is on treatment-resistant depression, or TRD, a subset of depressive disorder, or MDD, comprising patients who are inadequately served by the treatment paradigm. It has developed a proprietary, high-purity polymorphic crystalline formulation of psilocybin, COMP360.

Compass Pathways (FRA:5Y6) Headlines

No Headlines